VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial was testing vigabatrin for post-anoxic status epilepticus in patients who are in a coma — is that situation relevant to what my loved one is going through right now, and is this something worth discussing with you?
2. 2Since this was a Phase 2a feasibility study, it was mainly checking whether the drug could be absorbed and delivered safely rather than proving it works — what does that mean for how much we actually know about whether vigabatrin helps in this setting?
3. 3One of the things this trial was measuring was visual side effects, including a specific eye test called Goldmann Perimetry and taurine levels — can you explain why vigabatrin carries a risk to vision, and how serious that concern is for someone in this condition?
4. 4Now that this trial is completed, have any results been published, and do they change your thinking about vigabatrin as an option compared to the standard treatments you'd normally use for post-anoxic status epilepticus?
5. 5Since the trial focused on patients who are already in a coma with ongoing seizure activity on their brain waves, are there other treatment approaches you'd consider first before something like vigabatrin, and how do you decide when to try something less established?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.